Dr. Shuhao Wen, co-founder and president of XtalPi

XtalPi and CK Life Sciences to Collaborate in Research and Development of AI-Based Tumor Vaccines, Opening a New Paradigm for Scientific Innovation | BioSpace

AI-driven drug research and development (R&D) is breaking new ground, bringing faster and more effective treatment options to more patients worldwide

SHENZHEN and HONG KONG, China, Nov. 24, 2022 /PRNewswire/ — XtalPi announced today the launch of a strategic collaboration with CK Life Sciences, member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumor vaccine R&D platform to enhance tumor vaccine discovery and design capabilities and accelerate the development of more types of vaccines. The goal of this collaboration is to achieve precision treatment for patients around the world.

Dr. Shuhao Wen, co-founder and president of XtalPi

According to public information, there were nearly 20 million newly diagnosed cancer patients worldwide in 2021, of which about 4.5 million cases originated from China. Many types of cancer lead to adverse outcomes, with high morbidity and mortality, and there remains a significant unmet clinical need. Tumor vaccines targeting different neo-tumor antigens, tumor-associated antigens (TAA) and tumor-specific antigens (TSA) in patients can be designed for use as immunotherapy, to activate patient-specific immune responses.

Currently, there are only two therapeutic tumor vaccines, sipuleucel-T for melanoma and Bacillus Calmette-Guérin (BCG) for bladder cancer, as well as preventive tumor vaccines against infection with human papillomavirus and hepatitis B approved by the US Food and Drug Administration (FDA). Recently, several other tumor vaccines have entered clinical development and evidence of efficacy has begun to emerge.

According to Mordor Intelligence, the global cancer vaccines market size was 6.79 billion US$ in 2021 and will grow at a compound annual growth rate of 11.53% from 2022 to 2026. ‘by 2026 will be about 12 billion US dollars.

Currently, the design and preclinical development process of tumor vaccines is complex and time-consuming, which hampers the efficiency and success rate of tumor vaccine research and development.

Incorporating XtalPi’s industrial expertise in AI computation and robotic automation, this collaboration aims to create an AI tumor vaccine R&D platform that applies advanced AI algorithms and high-precision molecular modeling to predict and design a variety of tumor vaccines that can activate specific immune responses to kill tumors. Tumor vaccines will be screened and verified through automated experiments, and through the integration of algorithmic feedback to optimize potency and efficacy, the platform is expected to generate preclinical candidate vaccine compounds against tumors. tumors with robust immune activity.

Dr. Shuhao Wen, co-founder and chairman of XtalPi, commented, “As a company headquartered in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, XtalPi is committed to realizing the synergies between Shenzhen and Hong Kong by creating a new innovation paradigm in the Greater Bay Area. Empowered by the latest technological advances in automation, artificial intelligence is accelerating more innovative and diverse areas in drug research and development. Together with CK Life Sciences, we are committed to overcoming conventional limitations and discovering diverse applications for advanced technologies. We believe that the AI ​​cancer vaccine platform jointly developed by CK Life Sciences and XtalPi will inspire the global scientific community to advance vaccine research and development and accelerate key milestones in cancer vaccine development. We are confident that this collaboration will greatly facilitate the exchange of scientific research in the Bay Area Greater. »

Dr. Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, comments: “R&D of tumor vaccines is one of the main development directions of CK Life Sciences. Cooperation with XtalPi will apply XtalPi’s AI algorithm, molecular modeling and automated technology. experiments to speed up the R&D process, improve the success rate and increase the effectiveness of tumor vaccines.”

About XtalPi

Founded in 2014, the founders of XtalPi recognized a common obstacle in drug development related to solid polymorphism, which could be successfully solved through the predictions of quantum physics. Since then, XtalPi has focused on identifying and then solving traditional bottlenecks in biopharmaceutical R&D through innovative technologies. Thanks to significant capital investments in automation and personnel, XtalPi now has four locations worldwide and employs approximately 1000 employees. XtalPi has engaged in collaborative research with nearly all of the top 20 pharmaceutical companies in the world. Its ID4 platform combines physics-based simulations with experimental validation and refinement, automation for rapid synthesis, and machine learning to continuously improve prediction accuracy and process efficiency.

About CK Life Sciences

CK Life Sciences (stock code: 0775) is listed on the Hong Kong Stock Exchange. With a mission to improve the quality of life, CK Life Sciences is dedicated to researching and developing, manufacturing, marketing, selling, and investing in products and assets that fall into three main categories: nutraceuticals, pharmaceuticals and agriculture-related. CK Life Sciences is a member of the CK Hutchison Group.

Media contact:

Ruyu Wang
(617) 717-9867

Dr. Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences

XtalPi logo (PRNewsfoto/XtalPi Inc.)

Quote View original content to download multimedia: https://www.prnewswire.com/news-releases/xtalpi-and-ck-life-sciences-to-collaborate-in-ai-empowered-tumor-vaccine-research-and -development -opening-a-new-paradigm-for-scientific-innovation-301686858.html


#XtalPi #Life #Sciences #Collaborate #Research #Development #AIBased #Tumor #Vaccines #Opening #Paradigm #Scientific #Innovation #BioSpace

Leave a Comment

Your email address will not be published. Required fields are marked *